

Souheil El-Chemaly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8583846/publications.pdf>

Version: 2024-02-01

62
papers

1,936
citations

257357

24
h-index

265120

42
g-index

65
all docs

65
docs citations

65
times ranked

2977
citing authors

#	ARTICLE	IF	CITATIONS
1	Airway complications in lung transplant recipients with telomere-related interstitial lung disease. <i>Clinical Transplantation</i> , 2022, 36, e14552.	0.8	6
2	Interstitial lung abnormalities are associated with decreased mean telomere length. <i>European Respiratory Journal</i> , 2022, 60, 2101814.	3.1	8
3	ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells. <i>Life Science Alliance</i> , 2022, 5, e202201369.	1.3	2
4	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. <i>Frontiers in Medicine</i> , 2021, 8, 607720.	1.2	13
5	Editorial: Advances and Updates in Diffuse Cystic Lung Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 691688.	1.2	1
6	Intratracheal transplantation of trophoblast stem cells attenuates acute lung injury in mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 487.	2.4	1
7	CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 312-325.	2.5	24
8	Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	13
9	Blocking hyaluronan synthesis alleviates acute lung allograft rejection. <i>JCI Insight</i> , 2021, 6, .	2.3	4
10	The lung microbiome in end-stage Lymphangioleiomyomatosis. <i>Respiratory Research</i> , 2021, 22, 277.	1.4	0
11	Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. <i>ERJ Open Research</i> , 2020, 6, 00003-2020.	1.1	33
12	FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake. <i>Molecular Medicine</i> , 2020, 26, 75.	1.9	4
13	Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1710-1713.	2.5	108
14	Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. <i>European Respiratory Journal</i> , 2020, 55, 1902370.	3.1	7
15	Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres. <i>Frontiers in Immunology</i> , 2020, 11, 1063.	2.2	6
16	Lung transplant in familial pulmonary fibrosis: the road ahead. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200487-e20200487.	0.4	2
17	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019, 9, 14802.	1.6	12
18	Palmitic Acid-Rich High-Fat Diet Exacerbates Experimental Pulmonary Fibrosis by Modulating Endoplasmic Reticulum Stress. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 737-746.	1.4	73

#	ARTICLE	IF	CITATIONS
19	Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients. <i>Scientific Reports</i> , 2019, 9, 9003.	1.6	6
20	Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1131-1137.	1.5	22
21	Glycogen synthase kinase 3- β inhibition induces lymphangiogenesis through β -catenin-dependent and mTOR-independent pathways. <i>PLoS ONE</i> , 2019, 14, e0213831.	1.1	9
22	Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis-associated lymphangioleiomyomatosis. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 72.	1.2	5
23	Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2019, 54, 1900938.	3.1	5
24	Telomeres in Interstitial Lung Disease: The Short and the Long of It. <i>Annals of the American Thoracic Society</i> , 2019, 16, 175-181.	1.5	55
25	In-hospital and subsequent mortality among lung transplant recipients with a prolonged initial hospitalization. <i>American Journal of Transplantation</i> , 2019, 19, 532-539.	2.6	4
26	An Ethical Framework for the Care of Patients with Prolonged Hospitalization Following Lung Transplantation. <i>HEC Forum</i> , 2019, 31, 49-62.	0.6	5
27	Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 340-348.	0.3	30
28	Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 208-215.	1.4	56
29	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 153, 94-104.	0.4	66
30	Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients. <i>Annals of Thoracic Surgery</i> , 2018, 105, 441-447.	0.7	12
31	The impact of screening method on HLA antibody detection before and after lung transplantation: A prospective pilot study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 531-533.	0.3	4
32	Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. <i>Chest</i> , 2018, 154, 1070-1082.	0.4	13
33	[18 F]Fluorocholine and [18 F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM. <i>Clinical Cancer Research</i> , 2018, 24, 5925-5938.	3.2	8
34	The Immunome in Two Inherited Forms of Pulmonary Fibrosis. <i>Frontiers in Immunology</i> , 2018, 9, 76.	2.2	19
35	Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. <i>PLoS ONE</i> , 2018, 13, e0194193.	1.1	29
36	Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2018, 35, 206-212.	0.2	3

#	ARTICLE	IF	CITATIONS
37	The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. <i>European Respiratory Review</i> , 2017, 26, 160004.	3.0	13
38	Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 763-769.	0.3	55
39	Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. <i>Cancer Research</i> , 2017, 77, 1492-1502.	0.4	17
40	Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis. <i>Chest</i> , 2017, 151, 1302-1310.	0.4	46
41	Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 272-279.	1.4	41
42	Broadening the investigation short telomeres and lung transplantation outcomes in pulmonary fibrosis. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 833-834.	0.3	1
43	Lymphatic Vessels: The Next Frontier in Lung Transplant. <i>Annals of the American Thoracic Society</i> , 2017, 14, S226-S232.	1.5	26
44	The <i>MUC5B</i> promoter polymorphism is associated with specific interstitial lung abnormality subtypes. <i>European Respiratory Journal</i> , 2017, 50, 1700537.	3.1	55
45	Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. <i>JCI Insight</i> , 2017, 2, .	2.3	55
46	Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. <i>PLoS ONE</i> , 2016, 11, e0162409.	1.1	30
47	Predictors and outcomes of unplanned early rehospitalization in the first year following lung transplantation. <i>Clinical Transplantation</i> , 2016, 30, 1053-1058.	0.8	8
48	Genetics and Idiopathic Interstitial Pneumonias. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 321-330.	0.8	5
49	Hermansky-Pudlak Syndrome. <i>Clinics in Chest Medicine</i> , 2016, 37, 505-511.	0.8	82
50	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 672.	3.8	333
51	Donor-acquired fat embolism syndrome after lung transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1344-1347.	0.6	11
52	Short Telomeres, Telomeropathy, and Subclinical Extrapulmonary Organ Damage in Patients With Interstitial Lung Disease. <i>Chest</i> , 2015, 147, 1549-1557.	0.4	38
53	The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 195-204.	1.0	6
54	Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. <i>Journal of Clinical Investigation</i> , 2015, 125, 4255-4268.	3.9	79

#	ARTICLE	IF	CITATIONS
55	Transforming Growth Factor- β 1 Downregulates Vascular Endothelial Growth Factor-D Expression in Human Lung Fibroblasts via the Jun NH2-Terminal Kinase Signaling Pathway. <i>Molecular Medicine</i> , 2014, 20, 120-134.	1.9	33
56	Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 657-660.	1.0	20
57	Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. <i>European Respiratory Review</i> , 2014, 23, 30-35.	3.0	18
58	Glucose Transporter-1 Distribution in Fibrotic Lung Disease. <i>Chest</i> , 2013, 143, 1685-1691.	0.4	47
59	Natural History of Pulmonary Fibrosis in Two Subjects With the Same Telomerase Mutation. <i>Chest</i> , 2011, 139, 1203-1209.	0.4	47
60	Lymphatics in Idiopathic Pulmonary Fibrosis: New Insights into an Old Disease. <i>Lymphatic Research and Biology</i> , 2009, 7, 197-203.	0.5	26
61	Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3958-3963.	3.3	113
62	Lymphatics in Lung Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1131, 195-202.	1.8	63